FDA Clearance Tracker · P160002
VENTANA PD-L1(SP142) CDX ASSAY
Last checked: Nov 20, 2026Latest source record: May 18, 2016 (this decision)Source: openFDAMethods & limitations
Decided
May 18, 2016
Approved
Time to decision
126 days
Received Jan 13, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P160002
- Device name
- VENTANA PD-L1(SP142) CDX ASSAY
- Applicant
- Ventana Medical Systems, Inc.
- Applicant location
- Tucson, AZ
- Received
- Jan 13, 2016
- Decided
- May 18, 2016
- Decision
- Approved
- Supplements
- 21 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the PD-L1(SP142) Assay. The device is indicated for the following: VENTANA PD-L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP142 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) urothelial carcinoma tissue stained with OptiView DAB IHC Detection Kit and OptiView Amplifcation Kit on a VENTANA BenchMark ULTRA instrument. PD-L1 status is determined by the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity. PD-L1 expression in >= 5% IC determined by VENTANA PD-L1 (SP142) Assay in urothelial carcinoma tissue is associated with increased objective response rate (ORR) in a non-randomized study of TECENTRIQ (atezolizumab).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PLS. The earliest in FDA's data is P150013, decided Oct 2, 2015.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Ventana Medical Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- VENTANA HER2 Dual ISH DNA Probe CocktailPMA supplement
P190031-S016 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer (NYQ) · Laboratory Medicine & Pathology
P990081-S060 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: SYSTEM, TEST, HER-2/NEU, IHC (MVC) · Laboratory Medicine & Pathology
P250031 · Decided Jun 12, 2026 · 298 days after receipt
Device type: Immunohistochemistry Assay, Antibody (SHF) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.